Skip to main content
Top

07-11-2024 | Neuroblastoma | REVIEW ARTICLE

Recommendations for the use of nuclear medicine imaging in patients with neuroblastoma

Authors: Raquel Sánchez-Vañó, Julia Balaguer, Isabel Borrego-Dorado, Alba Esteban-Figueruelo, Cristina Gámez, Raquel Hladun, Ricardo López-Almaraz, Mercedes L. Llempén, Sonia Rodado, Pedro M. Rubio-Aparicio

Published in: Clinical and Translational Oncology

Login to get access

Abstract

Neuroblastoma (NB) is the most common extracranial solid cancer in children. Despite intensive multimodality treatment, long-term survival of patients with high-risk NB, which comprises more than half of all cases, remains poor. Nuclear medicine is key in diagnosis, staging, response assessment and long-term follow-up of NB. The emergence of novel tracers and the increasing complexity of studies require updated guidelines for nuclear medicine imaging in NB. Standardising diagnostic techniques are essential for improving study comparability and ensuring test quality. This article aims to provide a comprehensive review of NB radionuclide diagnostic imaging, including its characteristics, accuracy, advantages, and limitations. It offers practical recommendations to multidisciplinary teams responsible for treating patients with NB. This review summarises the opinions of leading experts from the Neuroblastoma Spanish Group within the Spanish Society of Paediatric Haematology and Oncology (SEHOP) and the Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM).
Appendix
Available only for authorised users
Literature
3.
go back to reference Samim A, Tytgat GAM, Bleeker G, Wenker STM, Chatalic KLS, Poot AJ, et al. Nuclear medicine imaging in neuroblastoma: current status and new developments. J Pers Med. 2021;11:270.PubMedPubMedCentralCrossRef Samim A, Tytgat GAM, Bleeker G, Wenker STM, Chatalic KLS, Poot AJ, et al. Nuclear medicine imaging in neuroblastoma: current status and new developments. J Pers Med. 2021;11:270.PubMedPubMedCentralCrossRef
4.
go back to reference Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Ash S, et al. Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN High-risk Neuroblastoma 1 Trial (HR-NBL1). Cancers. 2020;12:309.PubMedPubMedCentralCrossRef Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Ash S, et al. Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN High-risk Neuroblastoma 1 Trial (HR-NBL1). Cancers. 2020;12:309.PubMedPubMedCentralCrossRef
5.
go back to reference Gray J, Moreno L, Weston R, Barone G, Rubio A, Makin G, et al. BEACON-Immuno: results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC–International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial. J Clin Oncol. 2022;40:10002–10002.CrossRef Gray J, Moreno L, Weston R, Barone G, Rubio A, Makin G, et al. BEACON-Immuno: results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC–International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial. J Clin Oncol. 2022;40:10002–10002.CrossRef
6.
go back to reference Lode HN, Ehlert K, Huber S, Troschke-Meurer S, Siebert N, Zumpe M, et al. Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study. Br J Cancer. 2023;129:1780–6.PubMedPubMedCentralCrossRef Lode HN, Ehlert K, Huber S, Troschke-Meurer S, Siebert N, Zumpe M, et al. Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study. Br J Cancer. 2023;129:1780–6.PubMedPubMedCentralCrossRef
8.
go back to reference Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman MS, Lopci E, et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45:2009–24.PubMedCrossRef Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman MS, Lopci E, et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45:2009–24.PubMedCrossRef
10.
go back to reference Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:2436–46.PubMedCrossRef Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:2436–46.PubMedCrossRef
11.
go back to reference Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011;261:243–57.PubMedCrossRef Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011;261:243–57.PubMedCrossRef
25.
go back to reference Pfluger T, Piccardo A. Neuroblastoma: MIBG imaging and new tracers. Semin Nucl Med. 2017;47:143–57.PubMedCrossRef Pfluger T, Piccardo A. Neuroblastoma: MIBG imaging and new tracers. Semin Nucl Med. 2017;47:143–57.PubMedCrossRef
26.
go back to reference Bar-Sever Z, Giammarile F, Israel O, Nadel H, editors. A practical guide for pediatric nuclear medicine. Berlin [Heidelberg]: Springer; 2023. Bar-Sever Z, Giammarile F, Israel O, Nadel H, editors. A practical guide for pediatric nuclear medicine. Berlin [Heidelberg]: Springer; 2023.
27.
go back to reference Olecki E, Grant CN. MIBG in neuroblastoma diagnosis and treatment. Semin Pediatr Surg. 2019;28: 150859.PubMedCrossRef Olecki E, Grant CN. MIBG in neuroblastoma diagnosis and treatment. Semin Pediatr Surg. 2019;28: 150859.PubMedCrossRef
28.
go back to reference Jacobs A, Delree M, Desprechins B, Otten J, Ferster A, Jonckheer MH, et al. Consolidating the role of *I-MIBG-scintigraphy in childhood neuroblastoma: five years of clinical experience. Pediatr Radiol. 1990;20:157–9.PubMedCrossRef Jacobs A, Delree M, Desprechins B, Otten J, Ferster A, Jonckheer MH, et al. Consolidating the role of *I-MIBG-scintigraphy in childhood neuroblastoma: five years of clinical experience. Pediatr Radiol. 1990;20:157–9.PubMedCrossRef
29.
go back to reference Lumbroso J, Guermazi F, Hartmann O, Coornaert S, Rabarison Y, Lemerle J, et al. Sensitivity and specificity of meta-iodobenzylguanidine (mIBG) scintigraphy in the evaluation of neuroblastoma: analysis of 115 cases. Bull Cancer (Paris). 1988;75:97–106.PubMed Lumbroso J, Guermazi F, Hartmann O, Coornaert S, Rabarison Y, Lemerle J, et al. Sensitivity and specificity of meta-iodobenzylguanidine (mIBG) scintigraphy in the evaluation of neuroblastoma: analysis of 115 cases. Bull Cancer (Paris). 1988;75:97–106.PubMed
31.
go back to reference Liu B, Servaes S, Zhuang H. SPECT/CT MIBG imaging is crucial in the follow-up of the patients with high-risk neuroblastoma. Clin Nucl Med. 2018;43:232–8.PubMedCrossRef Liu B, Servaes S, Zhuang H. SPECT/CT MIBG imaging is crucial in the follow-up of the patients with high-risk neuroblastoma. Clin Nucl Med. 2018;43:232–8.PubMedCrossRef
32.
go back to reference Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, et al. Revisions to the international neuroblastoma response criteria: a consensus statement from the national cancer institute clinical trials planning meeting. J Clin Oncol. 2017;35:2580–7.PubMedPubMedCentralCrossRef Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, et al. Revisions to the international neuroblastoma response criteria: a consensus statement from the national cancer institute clinical trials planning meeting. J Clin Oncol. 2017;35:2580–7.PubMedPubMedCentralCrossRef
33.
go back to reference Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S, et al. Integrated imaging using MRI and 123 | metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. Am J Roentgenol. 2003;181:1115–24.CrossRef Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S, et al. Integrated imaging using MRI and 123 | metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. Am J Roentgenol. 2003;181:1115–24.CrossRef
34.
go back to reference Ladenstein R, Lambert B, Pötschger U, Castellani M-R, Lewington V, Bar-Sever Z, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2018;45:292–305.PubMedCrossRef Ladenstein R, Lambert B, Pötschger U, Castellani M-R, Lewington V, Bar-Sever Z, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2018;45:292–305.PubMedCrossRef
35.
go back to reference Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, et al. Validation of postinduction curie scores in high-risk neuroblastoma: a Children’s oncology group and SIOPEN Group Report on SIOPEN/HR-NBL1. J Nucl Med. 2018;59:502–8.PubMedPubMedCentralCrossRef Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, et al. Validation of postinduction curie scores in high-risk neuroblastoma: a Children’s oncology group and SIOPEN Group Report on SIOPEN/HR-NBL1. J Nucl Med. 2018;59:502–8.PubMedPubMedCentralCrossRef
36.
go back to reference Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s oncology group. J Nucl Med. 2013;54:541–8.PubMedCrossRef Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s oncology group. J Nucl Med. 2013;54:541–8.PubMedCrossRef
37.
go back to reference Rubio PM, Galán V, Rodado S, Plaza D, Martínez L. MIBG therapy for neuroblastoma: precision achieved with dosimetry, and concern for false responders. Front Med. 2020;7:173.CrossRef Rubio PM, Galán V, Rodado S, Plaza D, Martínez L. MIBG therapy for neuroblastoma: precision achieved with dosimetry, and concern for false responders. Front Med. 2020;7:173.CrossRef
38.
go back to reference Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JCA, et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial. Pediatr Blood Cancer. 2009;52:784–90.PubMedCrossRef Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JCA, et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial. Pediatr Blood Cancer. 2009;52:784–90.PubMedCrossRef
39.
go back to reference Ady N, Zucker JM, Asselain B, Edeline V, Bonnin F, Michon J, et al. A new 123I-MIBG whole body scan scoring method–application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer Oxf Engl. 1990;1995(31A):256–61. Ady N, Zucker JM, Asselain B, Edeline V, Bonnin F, Michon J, et al. A new 123I-MIBG whole body scan scoring method–application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer Oxf Engl. 1990;1995(31A):256–61.
40.
go back to reference Lewington V, Lambert B, Poetschger U, Sever ZB, Giammarile F, McEwan AJB, et al. 123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting, method by an international panel. Eur J Nucl Med Mol Imaging. 2017;44:234–41.PubMedCrossRef Lewington V, Lambert B, Poetschger U, Sever ZB, Giammarile F, McEwan AJB, et al. 123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting, method by an international panel. Eur J Nucl Med Mol Imaging. 2017;44:234–41.PubMedCrossRef
41.
go back to reference Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010;102:1319–26.PubMedPubMedCentralCrossRef Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010;102:1319–26.PubMedPubMedCentralCrossRef
42.
go back to reference Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiogr Rev Publ Radiol Soc N Am Inc. 2016;36:258–78. Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiogr Rev Publ Radiol Soc N Am Inc. 2016;36:258–78.
43.
go back to reference Melzer HI, Coppenrath E, Schmid I, Albert MH, Von Schweinitz D, Tudball C, et al. 123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging. 2011;38:1648–58.PubMedCrossRef Melzer HI, Coppenrath E, Schmid I, Albert MH, Von Schweinitz D, Tudball C, et al. 123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging. 2011;38:1648–58.PubMedCrossRef
44.
go back to reference Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588–601.PubMedCrossRef Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588–601.PubMedCrossRef
45.
go back to reference States LJ, Reid JR. Whole-body PET/MRI applications in pediatric oncology. Am J Roentgenol. 2020;215:713–25.CrossRef States LJ, Reid JR. Whole-body PET/MRI applications in pediatric oncology. Am J Roentgenol. 2020;215:713–25.CrossRef
46.
go back to reference Fortunati E, Argalia G, Zanoni L, Fanti S, Ambrosini V. New PET radiotracers for the imaging of neuroendocrine neoplasms. Curr Treat Options Oncol. 2022;23:703–20.PubMedPubMedCentralCrossRef Fortunati E, Argalia G, Zanoni L, Fanti S, Ambrosini V. New PET radiotracers for the imaging of neuroendocrine neoplasms. Curr Treat Options Oncol. 2022;23:703–20.PubMedPubMedCentralCrossRef
47.
go back to reference Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.PubMedCrossRef Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.PubMedCrossRef
48.
go back to reference Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289–97.PubMedPubMedCentralCrossRef Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289–97.PubMedPubMedCentralCrossRef
50.
go back to reference Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27:298–303.PubMedPubMedCentralCrossRef Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27:298–303.PubMedPubMedCentralCrossRef
52.
go back to reference Lanza C, Galeazzi V, Carboni N, De Berardinis A, De Marino L, Barile A, et al. Neuroblastoma image-defined risk factors in adrenal neuroblastoma: role of radiologist. Gland Surg. 2019;8:S168–77.PubMedPubMedCentralCrossRef Lanza C, Galeazzi V, Carboni N, De Berardinis A, De Marino L, Barile A, et al. Neuroblastoma image-defined risk factors in adrenal neuroblastoma: role of radiologist. Gland Surg. 2019;8:S168–77.PubMedPubMedCentralCrossRef
54.
go back to reference Lin KS, Uemura S, Thwin KKM, Nakatani N, Ishida T, Yamamoto N, et al. Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood. Transl Oncol. 2021;14: 101019.PubMedPubMedCentralCrossRef Lin KS, Uemura S, Thwin KKM, Nakatani N, Ishida T, Yamamoto N, et al. Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood. Transl Oncol. 2021;14: 101019.PubMedPubMedCentralCrossRef
56.
go back to reference Instituto de Investigacion Sanitaria La Fe. European Low and Intermediate Risk Neuroblastoma Protocol [Internet]. clinicaltrials.gov; 2019 Oct. Report No.: NCT01728155. Available from: https://clinicaltrials.gov/study/NCT01728155 Instituto de Investigacion Sanitaria La Fe. European Low and Intermediate Risk Neuroblastoma Protocol [Internet]. clinicaltrials.gov; 2019 Oct. Report No.: NCT01728155. Available from: https://​clinicaltrials.​gov/​study/​NCT01728155
57.
go back to reference Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GAM, et al. Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer. 2017;123:1095–105.PubMedCrossRef Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GAM, et al. Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer. 2017;123:1095–105.PubMedCrossRef
58.
go back to reference Streby KA, Parisi MT, Shulkin BL, LaBarre B, Bagatell R, Diller L, et al. Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2023;70: e30418.PubMedPubMedCentralCrossRef Streby KA, Parisi MT, Shulkin BL, LaBarre B, Bagatell R, Diller L, et al. Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2023;70: e30418.PubMedPubMedCentralCrossRef
59.
go back to reference Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with Stage 4 neuroblastoma: results of the cologne interscore comparison study. J Clin Oncol. 2013;31:944–51.PubMedCrossRef Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with Stage 4 neuroblastoma: results of the cologne interscore comparison study. J Clin Oncol. 2013;31:944–51.PubMedCrossRef
62.
go back to reference Morgenstern D, Barone G, Moreno L, Anderson J, Brock P, Elliott M, et al. Options for the treatment of patients with relapsed/progressive high-risk neuroblastoma. 2015;2. Morgenstern D, Barone G, Moreno L, Anderson J, Brock P, Elliott M, et al. Options for the treatment of patients with relapsed/progressive high-risk neuroblastoma. 2015;2.
63.
go back to reference Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M. Neuroblastoma. Jpn J Clin Oncol. 2018;48:214–41.PubMedCrossRef Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M. Neuroblastoma. Jpn J Clin Oncol. 2018;48:214–41.PubMedCrossRef
64.
go back to reference Simon T, Hero B, Schulte JH, Deubzer H, Hundsdoerfer P, von Schweinitz D, et al. 2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. Klin Padiatr. 2017;229:147–67.PubMedCrossRef Simon T, Hero B, Schulte JH, Deubzer H, Hundsdoerfer P, von Schweinitz D, et al. 2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. Klin Padiatr. 2017;229:147–67.PubMedCrossRef
66.
go back to reference St. Anna Kinderkrebsforschung. High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) [Internet]. clinicaltrials.gov; 2020 Oct. Report No.: NCT01704716. Available from: https://clinicaltrials.gov/study/NCT01704716 St. Anna Kinderkrebsforschung. High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) [Internet]. clinicaltrials.gov; 2020 Oct. Report No.: NCT01704716. Available from: https://​clinicaltrials.​gov/​study/​NCT01704716
68.
go back to reference DuBois SG, Macy ME, Henderson TO. High-risk and relapsed neuroblastoma: toward more cures and better outcomes. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet. 2022;42:1–13. DuBois SG, Macy ME, Henderson TO. High-risk and relapsed neuroblastoma: toward more cures and better outcomes. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet. 2022;42:1–13.
69.
go back to reference Yi ES, Son MH, Hyun JK, Cho HW, Ju HY, Lee JW, et al. Predictors of survival in patients with high-risk neuroblastoma who failed tandem high-dose chemotherapy and autologous stem cell transplantation. Pediatr Blood Cancer. 2020;67: e28066.PubMedCrossRef Yi ES, Son MH, Hyun JK, Cho HW, Ju HY, Lee JW, et al. Predictors of survival in patients with high-risk neuroblastoma who failed tandem high-dose chemotherapy and autologous stem cell transplantation. Pediatr Blood Cancer. 2020;67: e28066.PubMedCrossRef
70.
go back to reference Gauthé M, Breton M, Jehanno N, Cellier C, Michon J, Sarnacki S, et al. Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site. Q J Nucl Med Mol Imaging. 2020;64:131–8.PubMedCrossRef Gauthé M, Breton M, Jehanno N, Cellier C, Michon J, Sarnacki S, et al. Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site. Q J Nucl Med Mol Imaging. 2020;64:131–8.PubMedCrossRef
71.
go back to reference Seo ES, Shin M, Lim H, Cho HW, Ju HY, Cho Y-S, et al. Clinical implication of residual MIBG-positive disease in the follow-up of high-risk neuroblastoma treated with tandem high-dose chemotherapy and autologous stem cell transplantation. Pediatr Blood Cancer. 2022;69: e29502.PubMedCrossRef Seo ES, Shin M, Lim H, Cho HW, Ju HY, Cho Y-S, et al. Clinical implication of residual MIBG-positive disease in the follow-up of high-risk neuroblastoma treated with tandem high-dose chemotherapy and autologous stem cell transplantation. Pediatr Blood Cancer. 2022;69: e29502.PubMedCrossRef
72.
go back to reference Man S, Yan J, Li J, Cao Y, Hu J, Ma W, et al. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma. Int J Med Sci. 2021;18:1857–65.PubMedPubMedCentralCrossRef Man S, Yan J, Li J, Cao Y, Hu J, Ma W, et al. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma. Int J Med Sci. 2021;18:1857–65.PubMedPubMedCentralCrossRef
73.
go back to reference Hu R, Zhang Y, Liu S, Lee P, Liu C, Liu A. Prognostic prediction by 18F-FDG-PET/CT parameters in patients with neuroblastoma: a systematic review and meta-analysis. Front Oncol. 2023;13:1208531.PubMedPubMedCentralCrossRef Hu R, Zhang Y, Liu S, Lee P, Liu C, Liu A. Prognostic prediction by 18F-FDG-PET/CT parameters in patients with neuroblastoma: a systematic review and meta-analysis. Front Oncol. 2023;13:1208531.PubMedPubMedCentralCrossRef
74.
go back to reference Feng L, Zhang S, Wang C, Li S, Kan Y, Wang C, et al. Axial skeleton radiomics of 18F-FDG PET/CT: impact on event-free survival prediction in high-risk pediatric neuroblastoma. Acad Radiol. 2023;30:2487–96.PubMedCrossRef Feng L, Zhang S, Wang C, Li S, Kan Y, Wang C, et al. Axial skeleton radiomics of 18F-FDG PET/CT: impact on event-free survival prediction in high-risk pediatric neuroblastoma. Acad Radiol. 2023;30:2487–96.PubMedCrossRef
77.
go back to reference Jacobson AF, Travin MI. Impact of medications on mIBG uptake, with specific attention to the heart: comprehensive review of the literature. J Nucl Cardiol. 2015;22:980–93.PubMedCrossRef Jacobson AF, Travin MI. Impact of medications on mIBG uptake, with specific attention to the heart: comprehensive review of the literature. J Nucl Cardiol. 2015;22:980–93.PubMedCrossRef
78.
go back to reference Tratado de medicina nuclear en la práctica clínica. Carlos Andrés Achury Murcia; Ana María García Vicente, Josep Martin Comin, Angel Soriano Castrejón. Grupo Aula Médica S.L., 2019 (3 ed.). ISBN 978-84-7885-661-9. Tratado de medicina nuclear en la práctica clínica. Carlos Andrés Achury Murcia; Ana María García Vicente, Josep Martin Comin, Angel Soriano Castrejón. Grupo Aula Médica S.L., 2019 (3 ed.). ISBN 978-84-7885-661-9.
79.
go back to reference Gelfand MJ, Parisi MT, Treves ST. Pediatric Nuclear Medicine Dose Reduction Workgroup. Pediatric radiopharmaceutical administered doses: 2010 North American consensus guidelines. J Nucl Med. 2011;2011(52):318–22.CrossRef Gelfand MJ, Parisi MT, Treves ST. Pediatric Nuclear Medicine Dose Reduction Workgroup. Pediatric radiopharmaceutical administered doses: 2010 North American consensus guidelines. J Nucl Med. 2011;2011(52):318–22.CrossRef
80.
go back to reference Vali R, Alessio A, Balza R, Borgwardt L, Bar-Sever Z, Czachowski M, et al. SNMMI procedure standard/EANM practice guideline on pediatric 18 F-FDG PET/CT for oncology 1.0. J Nucl Med. 2021;62:99–110.PubMedPubMedCentralCrossRef Vali R, Alessio A, Balza R, Borgwardt L, Bar-Sever Z, Czachowski M, et al. SNMMI procedure standard/EANM practice guideline on pediatric 18 F-FDG PET/CT for oncology 1.0. J Nucl Med. 2021;62:99–110.PubMedPubMedCentralCrossRef
81.
go back to reference Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.PubMedCrossRef Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.PubMedCrossRef
87.
go back to reference Kroiss AS. Current status of functional imaging in neuroblastoma, pheochromocytoma, and paraganglioma disease. Wien Med Wochenschr. 1946;2019(169):25–32. Kroiss AS. Current status of functional imaging in neuroblastoma, pheochromocytoma, and paraganglioma disease. Wien Med Wochenschr. 1946;2019(169):25–32.
88.
go back to reference Piccardo A, Lopci E, Conte M, Garaventa A, Foppiani L, Altrinetti V, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging. 2012;39:57–71.PubMedCrossRef Piccardo A, Lopci E, Conte M, Garaventa A, Foppiani L, Altrinetti V, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging. 2012;39:57–71.PubMedCrossRef
91.
go back to reference Samim A, Blom T, Poot AJ, Windhorst AD, Fiocco M, Tolboom N, et al. [18F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2023;50:1146–57.PubMedCrossRef Samim A, Blom T, Poot AJ, Windhorst AD, Fiocco M, Tolboom N, et al. [18F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2023;50:1146–57.PubMedCrossRef
92.
go back to reference Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865–73.PubMedCrossRef Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865–73.PubMedCrossRef
93.
go back to reference Wang P, Li T, Liu Z, Jin M, Su Y, Zhang J, et al. [18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma. Eur J Nucl Med Mol Imaging. 2023;50:3097–106.PubMedCrossRef Wang P, Li T, Liu Z, Jin M, Su Y, Zhang J, et al. [18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma. Eur J Nucl Med Mol Imaging. 2023;50:3097–106.PubMedCrossRef
Metadata
Title
Recommendations for the use of nuclear medicine imaging in patients with neuroblastoma
Authors
Raquel Sánchez-Vañó
Julia Balaguer
Isabel Borrego-Dorado
Alba Esteban-Figueruelo
Cristina Gámez
Raquel Hladun
Ricardo López-Almaraz
Mercedes L. Llempén
Sonia Rodado
Pedro M. Rubio-Aparicio
Publication date
07-11-2024
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-024-03755-3
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now